Top news from MedWatch this week
Monday
Production limitations put a damper on Novo Nordisk’s potential growth
Eargo enters million-dollar settlement with the United States
Lundbeck veteran reflects as he nears 25-year anniversary: ”Don’t forget your roots”
Novo Nordisk remains coy over Wegovy blockbuster potential
Tuesday
Eli Lilly wants to gain on Novo Nordisk’s obesity lead
Demant predicts USD 14m impact of war in Ukraine in first ever quarterly report
Investors asked Demant for more transparency – now they have it
Novo Nordisk confirms start of phase I robotic pill trial
Leo Pharma takes hand eczema treatment into phase III
Wednesday
Ambu obtains CE mark for fifth generation single-use bronchoscope
Bose to drop hearing aid business, media reports
Analyst: Bose hearing aid exit reflects market complexity
EU proposes cross-border data space to strengthen health union
Thursday
GN Hearing beats analyst expectations for Q1
GN Hearing lets staff go to optimize supply chain
GN Hearing CEO: Bose’s exit spotlights complexity of hearing aid market
WS Audiology’s revenue grew by 20% in Q2 2021/2022
WSA maintains guidance despite strong growth – CEO explains why
Coloplast downgrades organic growth guidance
Ambu downgrades financial guidance
Friday
GN Hearing in talks with VA on new hybrid product category
Coloplast’s biggest ever acquisition lands firm USD 40m in two months
Potential buyers prepared to chase arimoclomol approval, Orphazyme deputy chair says
Coloplast will not exit Russia, says CEO
Ambu to reign in expectations after seventh downgrade since 2019
